Egalet Corporation (NASDAQ:EGLT) Q3 2019 Earnings Conference Call - Final Transcript
Nov 14, 2019 • 04:30 pm ET
Good afternoon, ladies and gentlemen and welcome to the Zyla 2019 Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, today's conference call is being recorded.
At this time, I'd like to turn the conference call over to Blair Clark-Schoeb. Please go ahead.
E. Blair Clark-Schoeb
Thanks, Jamie. Thank you all for joining us to discuss our third quarter 2019 financial results this afternoon. If you have not already received the press release you can find it on the zyla.com website under the Investors tab.
Leading this call today will be Todd Smith, Zyla President and CEO who is joined by Jesse Neri, VP of Finance.
During this call, management will make projections and other forward-looking remarks regarding future events and the company's future performance. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in this afternoon's press release and Zyla's filings with the SEC. Investors, potential investors and other listeners are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Actual results may differ materially from those projected in the forward-looking statements. Zyla specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. In addition, for the full prescribing information box warnings and medication guides of Zyla's marketed products, please visit our product page on zyla.com.
A telephone replay of the call will be available shortly after completion through Thursday, November 21. You can find the dial-in information in today's press release. The archived webcast will be available for six months on the company's website at zyla.com. For the benefit of those who may be listening to replay or the archived webcast, this call was held and reported on November 14, 2019. Since then Zyla may have made announcements related to the topics discussed, so please refer to the company's most recent press releases and SEC filings.
Now, I'll turn the call over to Todd. Todd?
Thanks, Blair. Good afternoon, everyone. Happy to be here after joining the company just a few weeks ago. Let me take a minute to share my initial thoughts about why I believe in the potential for Zyla, combination of an extensive and differentiated product portfolio with a potential for growth attracted me to this company. I believe that there is an opportunity to leverage much of the work that is ongoing combined with a number of potential new initiatives to improve growth and profitability. This will enable us to further serve the patients who depend of Zyla's products and build a strong and sustainable company, while driving value for investors. This is why I choose and chose to join Zyla. I look forward to working with the team to determine how we can take this company to the next level.
So, now let's turn the results from the third quarter. As a reminder, on January 31, 2019, the